U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H25NO
Molecular Weight 259.3865
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VESAMICOL, (±)-

SMILES

O[C@@H]1CCCC[C@H]1N2CCC(CC2)C3=CC=CC=C3

InChI

InChIKey=YSSBJODGIYRAMI-IAGOWNOFSA-N
InChI=1S/C17H25NO/c19-17-9-5-4-8-16(17)18-12-10-15(11-13-18)14-6-2-1-3-7-14/h1-3,6-7,15-17,19H,4-5,8-13H2/t16-,17-/m1/s1

HIDE SMILES / InChI

Molecular Formula C17H25NO
Molecular Weight 259.3865
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Vesamicol is an experimental drug, acting presynaptically by inhibiting acetylcholine (ACh) uptake into synaptic vesicles and reducing its release. Vesamicol (2-[4-phenylpiperidino] cyclohexanol) inhibits the transport of acetylcholine into synaptic vesicles in cholinergic nerve terminals. In addition to its effects on vesicular acetylcholine transport, vesamicol also possesses some sodium channel and alpha-adrenoceptor blocking activity. Vesamicol represents a unique tool for investigating presynaptic mechanisms in cholinergic nerve terminals. Vesamicol induced potent apoptosis of human BACs in cell culture and nude mice models. Vesamicol did not have any effect on EGF or insulin-like growth factor-II-induced growth of human bronchioalveolar carcinomas (BACs). siRNA-mediated attenuation of VAChT reversed the apoptotic activity of vesamicol. Vesamicol inhibited Akt phosphorylation during cell death and that overexpression of constitutively active Akt reversed the apoptotic activity of vesamicol. Disruption of nicotine-induced cholinergic signaling by agents such as vesamicol may have applications in BAC therapy.

Approval Year

PubMed

PubMed

TitleDatePubMed
Demonstration of a receptor in Torpedo synaptic vesicles for the acetylcholine storage blocker L-trans-2-(4-phenyl[3,4-3H]-piperidino) cyclohexanol.
1986 Apr
A further study of the neuromuscular effects of vesamicol (AH5183) and of its enantiomer specificity.
1988 Apr
The effects of l-vesamicol on transmitter release from rat motor nerve terminals at high frequencies of nerve stimulation.
1989 Dec
The effects of L-vesamicol, an inhibitor of vesicular acetylcholine uptake, on two populations of miniature endplate currents at the snake neuromuscular junction.
1990
Synthesis and evaluation of radiolabeled piperazine derivatives of vesamicol as SPECT agents for cholinergic neurons.
2001 Apr
Analysis of uptake and release of newly synthesized acetylcholine in PC12 cells overexpressing the rat vesicular acetylcholine transporter (VAChT).
2002 Apr 30
PET and SPET tracers for mapping the cardiac nervous system.
2002 Mar
Ethanol elevates accumbal dopamine levels via indirect activation of ventral tegmental nicotinic acetylcholine receptors.
2003 Apr 25
Structural changes of benzylether derivatives of vesamicol and their influence on the binding selectivity to the vesicular acetylcholine transporter.
2005 Dec
Synthesis and in vitro evaluation of new benzovesamicol analogues as potential imaging probes for the vesicular acetylcholine transporter.
2005 Feb 1
Mutational and pH analysis of ionic residues in transmembrane domains of vesicular acetylcholine transporter.
2005 Jun 7
Vesicles in snake motor terminals comprise one functional pool and utilize a single recycling strategy at all stimulus frequencies.
2005 Oct 15
New transport assay demonstrates vesicular acetylcholine transporter has many alternative substrates.
2005 Sep
Synthesis and binding affinities of methylvesamicol analogs for the acetylcholine transporter and sigma receptor.
2006 Apr 15
Release of acetylcholine by Hon-Chi to raise insulin secretion in Wistar rats.
2006 Aug 14
Release of acetylcholine to raise insulin secretion in Wistar rats by oleanolic acid, one of the active principles contained in Cornus officinalis.
2006 Aug 14
Increase of insulin secretion by ginsenoside Rh2 to lower plasma glucose in Wistar rats.
2006 Jan-Feb
Evaluation of (+)-p-[11C]methylvesamicol for mapping sigma1 receptors: a comparison with [11C]SA4503.
2006 May
Mutational and bioinformatics analysis of proline- and glycine-rich motifs in vesicular acetylcholine transporter.
2006 Sep
The potential of (-)-o-[11C]methylvesamicol for diagnosing cholinergic deficit dementia.
2009 Feb
Neuroimaging of the vesicular acetylcholine transporter by a novel 4-[18F]fluoro-benzoyl derivative of 7-hydroxy-6-(4-phenyl-piperidin-1-yl)-octahydro-benzo[1,4]oxazines.
2009 Jan
Evaluation of radioiodinated vesamicol analogs for sigma receptor imaging in tumor and radionuclide receptor therapy.
2009 Nov
Multiple protonation states of vesicular acetylcholine transporter detected by binding of [3H]vesamicol.
2009 Sep 29
Equilibrium binding and transport by vesicular acetylcholine transporter.
2010
Possible important pair of acidic residues in vesicular acetylcholine transporter.
2010 Apr 13
Synthesis and in vitro biological evaluation of carbonyl group-containing inhibitors of vesicular acetylcholine transporter.
2010 Apr 8
Enantioseparation of vesamicol and novel vesamicol analogs by high-performance liquid chromatography on different chiral stationary phases.
2010 Jun 11
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: I.p route in rats was used: to assess the effect of vesamicol in vivo, we examined cholinergic parameters, such as the subcellular distribution of ACh, activities of enzymes, uptake of choline, and muscarinic receptor binding in the striatum, hippocampus, and cerebral cortex of rats 30 and 60 min after intraperitoneal injection of vesamicol (3 mg/kg) or of vesamicol in combination with DDVP (5 mg/kg), which was administered 10 min before vasamicol. https://www.ncbi.nlm.nih.gov/pubmed/9205789
Nonhuman primates: Occupancy studies found that ~0.0057 mg/kg of (-)-vesamicol produced 50% VAChT occupancy in the striatum.
Route of Administration: Intravenous
In Vitro Use Guide
1. The effects of vesamicol, an inhibitor of vesicular acetylcholine (ACh) storage, were studied on trains of endplate currents (e.p.cs) in the cut rat hemidiaphragm nerve-muscle preparation and on trains of focally recorded nerve terminal current waveforms in the mouse triangularis sterni nerve-muscle preparation. 2. In the rat, 0.1 and 1 microM (-)-vesamicol produced an enhancement of the rundown of e.p.c. amplitudes during trains of high frequency (50 Hz) nerve stimulation. However, 1 microM (+)-vesamicol had no effect on the rundown of e.p.c. amplitudes. 3. In the mouse, high concentrations of (-)-vesamicol (10-100 microM) produced a concentration- and stimulation-dependent decrease in the amplitude of the second negative-going deflection of focally recorded nerve terminal current waveforms. 4. At 1 mM, (-)-vesamicol produced a stimulation-independent decrease in the amplitude of the first negative-going deflection of the nerve terminal current waveforms, an increase in signal delay and evidence of nerve conduction failure. These all indicate a local anaesthetic-like block of nodal Na(+)-channels. 5. In contrast to its effects on trains of e.p.cs, the effects of vesamicol on the nerve terminal current waveforms were not stereoselective, the (+)-isomer being equipotent with the (-)-isomer. 6. Low concentrations of the Na(+)-channel blocking toxin, tetrodotoxin (15-60 nM), produced similar changes in the focally recorded nerve terminal current waveforms to those seen with vesamicol. 7. It is concluded that the stereoselective rundown of e.p.c. amplitudes produced by (-)-vesamicol is due to an effect, either direct or indirect, on ACh mobilization within motor nerve terminals. Furthermore, in mammalian species, the inhibitory effects of vesamicol on nodal Na+-channels which are seen at high concentrations do not contribute to the principal neuromuscular effects of the compound.
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:55:45 GMT 2023
Edited
by admin
on Sat Dec 16 09:55:45 GMT 2023
Record UNII
3D416V0FLM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VESAMICOL, (±)-
Common Name English
2-(4-PHENYLPIPERIDIN-1-YL)CYCLOHEXAN-1-OL
Systematic Name English
VESAMICOL
Common Name English
CYCLOHEXANOL, 2-(4-PHENYL-1-PIPERIDINYL)-, TRANS-
Systematic Name English
CYCLOHEXANOL, 2-(4-PHENYL-1-PIPERIDINYL)-, TRANS-(±)-
Systematic Name English
AH5183
Code English
CYCLOHEXANOL, 2-(4-PHENYL-1-PIPERIDINYL)-, (1R,2R)-REL-
Systematic Name English
REL-(1R,2R)-2-(4-PHENYL-1-PIPERIDINYL)CYCLOHEXANOL
Common Name English
AH-5183
Code English
Code System Code Type Description
FDA UNII
3D416V0FLM
Created by admin on Sat Dec 16 09:55:46 GMT 2023 , Edited by admin on Sat Dec 16 09:55:46 GMT 2023
PRIMARY
SMS_ID
300000002058
Created by admin on Sat Dec 16 09:55:46 GMT 2023 , Edited by admin on Sat Dec 16 09:55:46 GMT 2023
PRIMARY
CAS
22232-64-0
Created by admin on Sat Dec 16 09:55:46 GMT 2023 , Edited by admin on Sat Dec 16 09:55:46 GMT 2023
NON-SPECIFIC STEREOCHEMISTRY
PUBCHEM
659840
Created by admin on Sat Dec 16 09:55:46 GMT 2023 , Edited by admin on Sat Dec 16 09:55:46 GMT 2023
PRIMARY
WIKIPEDIA
Vesamicol
Created by admin on Sat Dec 16 09:55:46 GMT 2023 , Edited by admin on Sat Dec 16 09:55:46 GMT 2023
PRIMARY
CAS
115362-28-2
Created by admin on Sat Dec 16 09:55:46 GMT 2023 , Edited by admin on Sat Dec 16 09:55:46 GMT 2023
PRIMARY
EPA CompTox
DTXSID701009898
Created by admin on Sat Dec 16 09:55:46 GMT 2023 , Edited by admin on Sat Dec 16 09:55:46 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
ACTIVE ENANTIOMER->RACEMATE